Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.
              
            
            
  
    
      
        Wu YX, Wan CL, Tan KW, Zhang Y, Zhang YM, Zhang H, Wu DP, Chen SN, Wang Y, Ma X, Dai HP, Qian CS, Jiang SS, Bao HY, Hu XH, Li Z, Xue SL.
        
      
    
    Wu YX, et al. Among authors: jiang ss.
    Clin Epigenetics. 2025 Oct 13;17(1):171. doi: 10.1186/s13148-025-01987-w.
    Clin Epigenetics. 2025.
  
  
  PMID: 41084078
  Free PMC article.
  
    
  
  Clinical Trial.